Bifunctional antagonists of activin / tgf-beta and rankl and uses thereof - Patent Application 20070122997
Patent Information
- Application Number
- JP2023526553
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-15
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000077_0000 
Figure 00000077_0001 
Figure 00000078_0000
Abstract
Claims
1. An isolated bifunctional antagonist molecule comprising a first antigen-binding molecule that specifically binds to RANKL, and a second antigen-binding molecule that specifically binds to a ligand selected from the group consisting of activin or an activin-related ligand or a TGF-β ligand, wherein the isolated bifunctional antagonist molecule simultaneously neutralizes activin- or TGF-β-mediated Smad signaling and RANKL-mediated NFκB signaling in a potent manner.
2. the first antigen-binding molecule that specifically binds to RANKL ("RANKL-binding polypeptide") is selected from the group consisting of an anti-RANKL antibody or a fragment of an anti-RANKL antibody, wild-type osteoprotegerin (OPG) as well as modified OPG, and a phage display-derived polypeptide having the ability to bind to and sequester RANKL; and the second antigen-binding molecule that specifically binds to activin or an activin-related ligand is selected from the group consisting of an anti-activin antibody (including anti-activin A and anti-activin B antibodies), an anti-activin antibody (including anti-activin B antibodies), an anti-activin antibody (including anti-activin A and anti-activin B antibodies), an anti-activin antibody (including anti-activin B antibodies), an anti-activin antibody (including anti-activin B antibodies), an anti-activin antibody (including anti-activin A antibodies), an anti-activin antibody (including ...
2. The isolated bifunctional antagonist molecule of claim 1, wherein the bifunctional antagonist molecule is selected from the group consisting of a polypeptide that is a cytoplasmic domain (CD) of a polypeptide that is a cytoplasmic domain ...
3. The isolated bifunctional antagonist molecule of any one of claims 1 to 2, wherein the second antigen-binding molecule specifically binds to an activin or activin-related ligand selected from the group consisting of activins or activin-related ligands comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 9.
4. The isolated bifunctional antagonist molecule of any one of claims 1 to 3, wherein the activin binding molecule is selected from the group of polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 1 to 17.
5. 4. The isolated bifunctional antagonist molecule of any one of claims 1 to 3, wherein the first antigen-binding molecule that specifically binds to RANKL ("RANKL-binding polypeptide") is selected from the group consisting of an anti-RANKL antibody or a fragment of an anti-RANKL antibody, wild-type osteoprotegerin (OPG) as well as modified OPG, and a phage display-derived polypeptide having the ability to bind and sequester RANKL; and the second antigen-binding molecule that specifically binds to a TGF-β ligand ("TGF-β binding polypeptide") is selected from the group consisting of an anti-TGF-β antibody, a fragment of an anti-TGF-β antibody, a wild-type TGF-β type 2 receptor (including TGF-βRIIA and TGF-βRIIB) extracellular domain (ECD), modified TGF-βRIIA and TGF-βRIIB extracellular domains, and a phage display-derived antagonist polypeptide that targets a TGF-β ligand.
6. 6. The isolated bifunctional antagonist molecule of claim 5, wherein the second antigen-binding molecule specifically binds to a TGF-β ligand selected from the group consisting of TGF-β ligands comprising the amino acid sequence set forth in SEQ ID NOs: 18-19.
7. 7. The isolated bifunctional antagonist molecule of any one of claims 5 to 6, wherein the TGF-β binding molecule is selected from the group of polypeptides comprising the amino acid sequences set forth in SEQ ID NOs: 18 to 23.
8. The isolated bifunctional antagonist molecule of any one of claims 1 to 7, wherein the RANKL binding molecule comprises an isolated anti-RANKL antibody, or an antigen-binding fragment thereof, the activin binding molecule comprises an isolated anti-activin antibody, or an antigen-binding fragment thereof, and the TGF-β binding molecule comprises an isolated anti-TGF-β antibody, or an antigen-binding fragment thereof.
9. 9. The isolated bifunctional antagonist molecule of claim 8, wherein the isolated anti-RANKL antibody or antigen-binding fragment thereof, isolated anti-activin antibody or antigen-binding fragment thereof, and isolated anti-TGF-β antibody or antigen-binding fragment thereof is selected from the group consisting of monoclonal Abs (mAbs), polyclonal Abs, Ab fragments (e.g., Fab, Fab', F(ab')2, Fv, Fc, etc.), chimeric Abs, miniAbs or domain Abs (dAbs), bispecific Abs, bispecific Abs, heteroconjugate Abs, single chain Abs (SCAs), single chain variable fragments (ScFvs), humanized Abs, fully human Abs, and any other modified configuration of an immunoglobulin (Ig) molecule that contains an antigen recognition site of the required specificity.
10. 10. The isolated bifunctional antagonist molecule of any one of claims 8 to 9, wherein the isolated antibody or antigen-binding fragment thereof is selected from the group consisting of fully human, humanized and chimeric antibodies.
11. 11. The isolated bifunctional antagonist molecule of any one of claims 8 to 10, wherein the RANKL-binding molecule is an isolated antibody selected from the group consisting of an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:24; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:25; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:24 and a light chain amino acid sequence set forth in SEQ ID NO:25; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:26; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:27; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:26 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
27.
12. 12. The isolated bifunctional antagonist molecule of any one of claims 8-11, wherein the activin binding molecule is an isolated antibody selected from the group consisting of an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 10; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO: 11; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 10 and a light chain amino acid sequence set forth in SEQ ID NO: 11; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 12; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO: 13; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 12 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 13; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 14; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO: 15; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 14 and a light chain variable region amino acid sequence set forth in SEQ ID NO: 15; an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO: 14 and a light chain amino acid sequence set forth in SEQ ID NO: 15; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 16; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO: 17; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO: 16 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
17.
13. 12. The isolated bifunctional antagonist molecule of any one of claims 8-11, wherein the TGF-beta binding molecule is an isolated antibody selected from the group consisting of an antibody comprising a heavy chain amino acid sequence set forth in SEQ ID NO:20; an antibody comprising a light chain amino acid sequence set forth in SEQ ID NO:21; an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:22; an antibody comprising a light chain variable region amino acid sequence set forth in SEQ ID NO:23; and an antibody comprising a heavy chain variable region amino acid sequence set forth in SEQ ID NO:22 and a light chain variable region amino acid sequence set forth in SEQ ID NO:
23.
14. 2. The isolated bifunctional antagonist molecule of claim 1, comprising an amino acid sequence selected from the group consisting of the amino acid sequences set forth in SEQ ID NOs: 40-48 and 51-52.
15. 2. The isolated bifunctional antagonist molecule of claim 1, comprising a heavy chain selected from the group consisting of heavy chains comprising the amino acid sequence set forth in SEQ ID NO:29-39 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:
25.
16. The isolated bifunctional antagonist molecule of claim 1, selected from the group consisting of: an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:49 and a light chain amino acid sequence set forth in SEQ ID NO:11; an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:50 and a light chain amino acid sequence set forth in SEQ ID NO:15; and an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:53 and a light chain amino acid sequence set forth in SEQ ID NO:
21.
17. 2. The isolated bifunctional antagonist molecule of claim 1, wherein the bifunctional antagonist molecule is selected from the group consisting of: an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:24, a light chain amino acid sequence set forth in SEQ ID NO:25, a heavy chain amino acid sequence set forth in SEQ ID NO:10, and a light chain amino acid sequence set forth in SEQ ID NO:11; an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:24, a light chain amino acid sequence set forth in SEQ ID NO:25, a heavy chain amino acid sequence set forth in SEQ ID NO:14, and a light chain amino acid sequence set forth in SEQ ID NO:15; an isolated bifunctional antagonist molecule comprising a heavy chain amino acid sequence set forth in SEQ ID NO:24, a light chain amino acid sequence set forth in SEQ ID NO:25, a heavy chain amino acid sequence set forth in SEQ ID NO:20, and a light chain amino acid sequence set forth in SEQ ID NO:
21.
18. A pharmaceutical composition comprising a therapeutically effective amount of the isolated bifunctional antagonist molecule of any one of claims 1 to 17 in admixture with a pharma- ceutically acceptable carrier.
19. The pharmaceutical composition according to claim 18, for treating or preventing a disease state whose pathogenesis involves activation of both the RANKL-NFκB signaling pathway and the Activin / TGFβ-Smad2 / 3 signaling pathway.
20. 20. The pharmaceutical composition of claim 19, wherein the disease state is selected from the group consisting of bone metastasis and skeletal-related events in cancer, osteolytic neoplasms such as giant cell tumor of bone (GCTB) and multiple myeloma; osteolytic lesions; bone fractures; osteoporosis; glucocorticoid therapy-induced osteopenia; androgen deprivation therapy-induced osteopenia; muscle wasting disorders associated with osteopenia such as cancer cachexia, sarcopenia, muscular dystrophies, spinal muscular atrophies; and osteogenesis imperfecta.
21. The pharmaceutical composition according to any one of claims 19 to 20, wherein the cancer is selected from the group consisting of melanoma, multiple myeloma, lung cancer, pancreatic cancer, colorectal cancer, liver cancer, gastric cancer, kidney cancer, bladder cancer, head and neck cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, testicular cancer, prostate cancer and brain cancer.
22. A combination pharmaceutical for treating or preventing a disease state whose pathogenesis involves activation of both the RANKL-NFκB signaling pathway and the activin / TGFβ-Smad2 / 3 signaling pathway, the pharmaceutical comprising: (i) a pharmaceutical composition according to claim 21; and (ii) an immune checkpoint inhibitor selected from the group consisting of anti-PD1, anti-PDL1, and anti-CTL4 antibodies; A combination medicine comprising:
23. An isolated nucleic acid molecule comprising a polynucleotide encoding the bifunctional antagonist molecule of any one of claims 1 to 17.
24. A recombinant vector comprising the nucleic acid molecule of claim 23.
25. A host cell comprising the recombinant vector of claim 24.
26. 18. A method for producing a bifunctional antagonist molecule according to any one of claims 1 to 17, comprising the steps of: a) transforming a host cell with a vector comprising a polynucleotide encoding said bifunctional antagonist molecule; b) culturing said host cell under conditions suitable for expression of said bifunctional antagonist molecule; and c) recovering said bifunctional antagonist molecule from the culture.
